Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.17%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.17, delivering a surprise of 6.25%.Over the last four quarters, the company has ...

Exhibit 99.1 Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance VAUGHAN, Ontario, Feb. 19, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full year 2024 financial results. "Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now ...

Core Insights - Bausch + Lomb (BLCO) is expected to report quarterly earnings of $0.24 per share, indicating no change from the previous year, with revenues forecasted at $1.27 billion, reflecting a 7.9% year-over-year increase [1] Earnings Estimates - The consensus EPS estimate has been revised 5.8% lower over the last 30 days, indicating a reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts predict 'Revenue- Vision Care' at $708.34 million, suggesting a 7% year-over-year increase [5] - 'Revenue- Pharmaceuticals' is estimated to be $335.50 million, indicating a 9.3% year-over-year increase [5] - 'Revenue- Product sales' is expected to reach $1.26 billion, reflecting a 7.7% year-over-year increase [5] - 'Revenue- Surgical' is forecasted at $215.26 million, indicating a 5.5% increase from the prior year [6] - 'Revenue- Other' is projected to be $5.00 million [6] Stock Performance - Bausch + Lomb shares have shown a return of -5.5% over the past month, contrasting with the Zacks S&P 500 composite's +4.7% change, indicating underperformance [7] - The company holds a Zacks Rank 4 (Sell), suggesting it is expected to lag the overall market performance in the near future [7]

Financial Performance - Revenues for the three months ended September 30, 2024, were $1,196 million, an increase of $189 million, or 19%, compared to $1,007 million in the same period of 2023[231]. - Total revenues for Q3 2024 reached $1,196 million, a 19% increase from $1,007 million in Q3 2023[236]. - Total revenues for the nine months ended September 30, 2024, were $3,511 million, an 18% increase from $2,973 million in the same period of 2023, driven by acquisitions and increased volumes[274]. - Vision Care segment revenue was $2,016 million for the nine months ended September 30, 2024, a 7% increase from $1,881 million in 2023, primarily due to sales from the dry eye portfolio and Lumify[278]. - Pharmaceuticals segment revenue increased to $883 million for the nine months ended September 30, 2024, a 67% rise from $529 million in 2023, driven by the XIIDRA acquisition and the launch of MIEBO[279]. - Surgical segment revenue was $612 million for the nine months ended September 30, 2024, a 9% increase from $563 million in 2023, driven by increased demand for consumables and implantables[282]. Income and Expenses - Operating income for the three months ended September 30, 2024, was $43 million, compared to $40 million in the same period of 2023, reflecting a slight increase[231]. - Net income attributable to Bausch + Lomb Corporation for the three months ended September 30, 2024, was $4 million, a significant improvement from a net loss of $84 million in the same period of 2023[231]. - Selling, general, and administrative expenses rose to $511 million for the three months ended September 30, 2024, up from $418 million in 2023, reflecting an increase of $93 million[231]. - Research and development expenses were $84 million for the three months ended September 30, 2024, slightly up from $82 million in the same period of 2023[231]. - Interest expense increased to $100 million for Q3 2024, up from $76 million in Q3 2023, primarily due to new debt associated with the October 2028 Secured Notes[268]. - Operating income decreased by $6 million, or 7%, to $75 million for the nine months ended September 30, 2024, from $81 million in 2023[291]. Product Development and Launches - The company has a pipeline of approximately 60 projects in various stages of pre-clinical and clinical development, including new contact lenses for myopia and next-generation cataract equipment[199]. - The company launched SiHy Daily, a silicone hydrogel daily disposable contact lens, in over 50 countries and plans to continue its global rollout[201]. - MIEBO, the first FDA-approved treatment for dry eye disease targeting tear evaporation, was launched in the U.S. in September 2023 and approved in Canada in September 2024[202]. - The company acquired XIIDRA, a non-steroid eye drop for dry eye disease, from Novartis in September 2023, enhancing its dry eye franchise[205]. - The acquisition of Trukera Medical in July 2024 is expected to expand the company's presence in the dry eye market with its point-of-care device for measuring tear osmolarity[205]. - The enVista Aspire monofocal and toric IOLs launched in the U.S. in October 2023, with plans for European and Canadian launches in 2025[204]. Market and Competitive Position - The company’s Vision Care segment includes a comprehensive portfolio of contact lenses and consumer eye care products, contributing to its competitive position in the eye health market[193]. - Vision Care segment revenue increased to $684 million in Q3 2024, up 6% from $648 million in Q3 2023, driven by dry eye portfolio sales and SiHy Daily lenses[241]. - Pharmaceuticals segment revenue surged to $306 million in Q3 2024, a 76% increase from $174 million in Q3 2023, primarily due to the XIIDRA acquisition and MIEBO launch[243]. - Surgical segment revenue rose to $206 million in Q3 2024, an 11% increase from $185 million in Q3 2023, attributed to higher demand for consumables and implantables[244]. Debt and Financial Obligations - As of September 30, 2024, the principal amounts outstanding under the May 2027 Term Facility and September 2028 Term Facility were $2,444 million and $495 million, respectively[315]. - The Company issued $1,400 million aggregate principal amount of 8.375% Senior Secured Notes due October 2028, with interest payable semi-annually starting April 1, 2024[325]. - The weighted average stated rate of interest for the Company's outstanding debt obligations as of September 30, 2024, was 8.34%[330]. - The Company expects to make interest payments of approximately $130 million and mandatory debt amortization payments of $8 million for the period October 1, 2024, through December 31, 2024[335]. - The amortization rate for the May 2027 Term Facility is 1.00% per annum, or $25 million, payable in quarterly installments[323]. - The amortization rate for the September 2028 Term Facility is 1.00% per annum, or $5 million, payable in quarterly installments[324]. Risks and Challenges - The company faces risks related to adverse economic conditions, including inflation and potential recession, which could impact revenues and margins[350]. - The introduction of generic and biosimilar competitors poses a risk to the company's branded products and market share[357]. - The company is committed to obtaining and maintaining sufficient intellectual property rights to protect its products from competition[358]. - The impact of geopolitical conflicts, including those in Russia and Ukraine, is being closely monitored as it may affect sales and operations[356]. - The company faces risks related to potential work stoppages, economic factors, and compliance with extensive regulations, which could impact operations and financial performance[359]. - The company must navigate uncertainties in drug development, including the success of clinical trials and regulatory approvals, which could impact the commercialization of its products[359]. Strategic Initiatives - The Company plans to refinance its debt upon full separation and transition to a longer-term capital structure[332]. - The company anticipates continued improvement in operational efficiency and plans to enhance cash and working capital requirements for the remainder of 2024 and beyond[348]. - Expected revenues for the company's products, including XIIDRA, are anticipated to grow, with specific R&D and marketing expenditures outlined[348]. - The company is actively managing challenges post-IPO, including potential conflicts of interest and the complexities of operating as an independent entity[350]. - The company is focused on maintaining strong relationships with healthcare professionals and ensuring favorable formulary status for its products[356].

Financial Data and Key Metrics Changes - Total company revenue for Q3 2024 was $1.196 billion, reflecting a growth of 19% and 10% on an organic basis [17][18] - Adjusted gross margin for Q3 was 63%, up 170 basis points compared to Q3 2023, driven by a transition to higher-margin products [28] - Adjusted EBITDA, excluding acquired IP R&D, was $227 million, representing 21% growth versus Q3 2023 [30] Business Line Data and Key Metrics Changes - Vision Care segment revenue was $684 million, increasing by 6%, with notable growth in the consumer dry eye portfolio, which delivered $93 million in revenue, representing 19% growth [19][20] - Surgical segment revenue was $206 million, an increase of 12%, with consumables growing by 14% and premium IOLs up 23% [23][24] - Pharma segment revenue was $306 million, representing growth of 76% and organic growth of 25%, with Miebo delivering $49 million and Xiidra contributing $92 million [25][26] Market Data and Key Metrics Changes - Contact lens revenue growth was 12%, with the U.S. up 13% and international markets up 11%, particularly strong growth in China at 16% [21][22] - The broader consumer market in the U.S. experienced disruptions, impacting the eye vitamins franchise, which was down 9% in Q3 [20] Company Strategy and Development Direction - The company is focused on a relentless execution strategy, emphasizing sales excellence, operational excellence, and innovation [7][55] - There is a strategic shift towards a higher-margin product portfolio, with ongoing investments in R&D and digital capabilities [9][29] - The company is committed to a full separation from Bausch Health, exploring multiple paths to achieve this [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum and strong performance, expecting continued revenue growth and future margin expansion [36] - The company is closely monitoring the impact of the Inflation Reduction Act and balancing TRx growth with access to coverage for patients [33][60] Other Important Information - The company raised its full-year revenue guidance to a range of $4.725 billion to $4.825 billion, reflecting strong performance from Miebo and lower expected currency headwinds [32] - The launch of Opal, a digital e-commerce marketplace, aims to streamline ordering processes for contact lenses, enhancing customer experience [45][46] Q&A Session Summary Question: What has been the biggest factor in the company's current success? - Management highlighted a clear strategy focused on sales excellence, operational excellence, and innovation, with a relentless focus on execution leading to broad-based performance [53][55] Question: How sustainable is the growth in the dry eye portfolio? - Management noted strong performance in the dry eye portfolio, with Miebo and Xiidra driving growth, and emphasized the importance of a holistic approach to treating dry eye disease [59][60] Question: What are the expectations for Xiidra sales in 2025? - Management indicated that while there are headwinds expected from the Inflation Reduction Act, they anticipate continued volume growth for Xiidra [69] Question: What is the expected impact of direct-to-consumer campaigns for Xiidra and Miebo? - Management expressed optimism about the early results of the campaigns, noting that they will continue to invest based on ROI analysis [72][73]

For the quarter ended September 2024, Bausch + Lomb (BLCO) reported revenue of $1.2 billion, up 18.8% over the same period last year. EPS came in at $0.17, compared to $0.22 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +6.25%, with the consensus EPS estimate being $0.16. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.25%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.13, delivering no surprise. Over the last four quarters, the company has surpas ...

Exhibit 99.1 Bausch + Lomb Announces Third-Quarter 2024 Results • Revenue of $1.196 Billion • GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million • Adjusted EBITDA (non-GAAP) of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (nonGAAP) of $227 Million • Revenue Grew 19% as Reported and 19% on a Constant Currency Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments • Raising Full-Year 2024 Revenue Guidance 1 1 1 VAUGHAN, Ontario, Oct ...

It was quite a busy and eventful day for the company. Monday was an eventful day for Bausch + Lomb (BLCO 7.19%). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval. As if that weren't enough, media reports claimed that the company has put itself up for sale. Buffeted by these strong winds, Bausch + Lomb's stock price rose over 7% in the day's trading session. Eyes on the prize Of the two news items, the buyout one had the bigger i ...

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors. These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Also Read: Photo by JHVEPhoto via Shutterstock ...